Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Protocol for determining zinc-dependent beta cell-selective small-molecule delivery in mouse pancreas. STAR protocols Horton, T. M., Kraemer, B. R., Annes, J. P. 2021; 2 (1): 100263

Abstract

Targeted drug delivery to pancreatic islet beta cells is an unmet clinical need. beta cells possess a uniquely high Zn2+ concentration, and integrating Zn2+-binding activity into a small molecule can bias drug accumulation and activity toward beta cells. This protocol can be used to evaluate a molecule's capacity to chelate islet Zn2+, accumulate in islets, and stimulate beta cell-selective replication in mouse pancreas. One obstacle is establishing an LC-MS/MS-based method for compound measurement. Limitations include target compound ionizability and the time-sensitive nature of some experimental assay steps. For complete details on the use and execution of this protocol, please refer to Horton etal. (2019).

View details for DOI 10.1016/j.xpro.2020.100263

View details for PubMedID 33490979